Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Rituximab

5

XVII.a Respiratory tract infection incl. pneumonia

3
Last update : 18/09/2022
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Anti-CD20 antibody therapy
4

Publications

Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort.
Clinical rheumatology 2022 Sep;41;2809-2816 2022 Sep
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report.
Drug safety - case reports 2018 May 11;5;22 2018 May 11
Rituximab in severe, treatment-refractory interstitial lung disease.
Respirology (Carlton, Vic.) 2014 Apr;19;353-9 2014 Apr

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies